As you will be aware, the Department for Health & Social Care has asked NICE to conduct an appraisal of Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-April 2023.